APM Aptorum Group

Aptorum Group Interview to Air on Bloomberg International on the RedChip Money Report

NEW YORK--(BUSINESS WIRE)--

Regulatory News:

Aptorum Group Limited (NASDAQ: APM), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced an interview with its President, Daniel Lui, will air on The RedChip Money Report television program. The interview will air Sunday, August 30, at 6 p.m. local time on Bloomberg International, available in 100+ million homes across Europe.

In the exclusive interview, Lui provides an overview of the Company’s development pipeline and near-term commercialization efforts.

To view the interview segment, please visit:

The interview will also air in the US on the Action Channel on Sunday August 30 at 11 a.m. ET and is available via live stream on American Business TV.

“The RedChip Money Report" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.

About Aptorum Group

Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum Group’s current drug pipeline includes indications in orphan diseases, infectious diseases and metabolic diseases and a number of which are targeted to enter clinical trial phases in 2020. Aptorum Group also operates a women’s health supplement business whose Dioscorea opposita Bioactive Nutraceutical Tablets are currently being commercialized.

For more information about the Company, please visit .

EN
28/08/2020

Underlying

APMAptorum Group

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aptorum Group

 PRESS RELEASE
Free
APM APTORUM GROUP

Aptorum Group Announces Completion of Pre-IND Discussions with US FDA ...

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announces the completion of the Pre-IND discussions with the US Food and Drug Administration (“US FDA”). ALS-4 is a first-in-class small molecule anti-virulence drug targeting infections caused by Staphylococcus aureus, including but not limited to Methicillin Resistant Staphylococcus Aureus (“MRSA”). Upon the completion of ALS-4’s respective Phase I clinical trials in Canada, ALS-4 has been targetin...

March 3, 2023 1 EN
 PRESS RELEASE
Free
APM APTORUM GROUP

Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting wi...

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announces the completion of an end of Phase 1 (EOP1) meeting with the US Food and Drug Administration (“US FDA”). SACT-1 is a repurposed small molecule drug formulated in oral suspension targeting neuroblastoma in pediatric patients and has also received orphan drug designation previously from the US FDA. The EOP1 meeting was focused on gaining alignment with the US FDA regarding the clinical and reg...

March 3, 2023 1 EN
 PRESS RELEASE
Free
APM APTORUM GROUP

Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopau...

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group”), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics to tackling unmet medical needs, announces the exciting commercial launch of NativusWell®, a new dietary supplement supporting women’s health throughout the Menopausal cycles targeting the China market. NativusWell® has commenced collaboration with one of the largest e-commerce platforms in China, JD.com, and NativusWell® is now distributable in China via JD. China ...

March 2, 2023 1 EN
 PRESS RELEASE
Free
APM APTORUM GROUP

Aptorum Group Limited to Hold Special Extraordinary Meeting of Shareho...

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced that it will hold a special extraordinary meeting of shareholders at the London office 4T.07, 17 Hanover Square, Mayfair London, England W1S 1BN at 10:00 a.m. London Time on February 21, 2023 (5:00 a.m. Eastern Standard Time on February 21, 2023 / 10:00 a.m. Greenwich Mean Time on February...

February 6, 2023 1 EN
 PRESS RELEASE
Free
APM APTORUM GROUP

Aptorum Group Announces 1-for-10 Reverse Stock Split

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (the “Company”) a clinical stage biopharmaceutical company dedicated to tackling unmet medical needs in oncology, autoimmune and infectious diseases, today announced a 1-for-10 reverse stock split of the Company's Class A Ordinary Shares, effective at 12:01 a.m. Eastern Time on January 23, 2023. The Company’s Class A Ordinary Shares is expected to commence trading on a split-adjusted basis when the markets open on January 23, 2023. The Company’s Class B Ordinary Shares shall ...

January 20, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch